Daesoon Leem, MD
Sports Medicine · Los Angeles, CANPI 1902289226
Payments from drug & device makers
Across 61 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$471
- AbbVie$252
- AstraZeneca$211
- Lilly USA, LLC$167
- Nestle Healthcare Nutrition Inc.$147
- GSK$146
- plus $1K from 22 others
What the payments were for
- Travel & lodging$120%
- Food & beverage$2,865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 7 | $471 |
| AbbVie | 2 | $252 |
| AstraZeneca(2 entities) | 7 | $211 |
| Lilly USA, LLC | 3 | $167 |
| Nestle Healthcare Nutrition Inc. | 2 | $147 |
| GSK | 2 | $146 |
| Novo Nordisk | 2 | $136 |
| Halozyme Inc | 1 | $127 |
| Amgen | 3 | $126 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| Eisai Inc. | 1 | $113 |
| Radius Health, Inc. | 1 | $101 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $86 |
| Bioventus LLC | 3 | $77 |
| Boehringer Ingelheim | 3 | $76 |
| IBSA Pharma Inc. | 1 | $68 |
| Dexcom, Inc. | 3 | $67 |
| Pacira Therapeutics, Inc. | 2 | $61 |
| Abiomed | 3 | $58 |
| Ironwood Pharmaceuticals, Inc | 3 | $56 |
| Revance Therapeutics, Inc. | 2 | $50 |
| Samsung HME America, Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Zimmer Biomet | 1 | $22 |
| Medline Industries LP | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Gilead | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,877 in reported general payments places this provider in the 50th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 54 | $71,074 |
| JardianceEmpagliflozin | 61 | $42,921 |
| LinzessLinaclotide | 43 | $35,356 |
| VascepaIcosapent Ethyl | 75 | $31,990 |
| TrulicityDulaglutide | 22 | $26,313 |
| OzempicSemaglutide | 22 | $25,943 |
| KerendiaFinerenone | 31 | $23,766 |
| ZenpepLipase/Protease/Amylase | 24 | $23,004 |
| ProliaDenosumab | 14 | $22,731 |
| EliquisApixaban | 27 | $22,702 |
| FarxigaDapagliflozin Propanediol | 28 | $20,803 |
| JanuviaSitagliptin Phosphate | 34 | $20,028 |
| TradjentaLinagliptin | 31 | $15,839 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $13,083 |
| Icosapent Ethyl | 42 | $9,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $252 | $106,43097 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $76 | $71,842110 claims |
| Lilly USA, LLCTrulicity | $167 | $26,31322 claims |
| Novo NordiskOzempic | $136 | $25,94322 claims |
| BayerKerendia | $471 | $23,76631 claims |
| Aimmune Therapeutics, Inc.Zenpep | $21 | $23,00424 claims |
| AmgenProlia | $126 | $22,73114 claims |
| AstraZenecaFarxiga | $211 | $20,80328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 662 sports medicine providers in California.
Other sports medicine in Los Angeles
- Neal ElattracheLos Angeles$51M
- Carleton VangsnessLos Angeles$872K
- Kristofer JonesLos Angeles$605K
- Michael BanffyLos Angeles$578K
- Seth GamradtLos Angeles$567K
- Reza OmidLos Angeles$400K
- Orr LimpisvastiLos Angeles$335K
- George HatchLos Angeles$255K
- David McAllisterLos Angeles$186K
- Stephen LiuLos Angeles$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.